Dataset

Treatment-Resistant Schizophrenia Biobank

Also known as: Schizophrenia Biobank, TRS
The University of Melbourne
1.Christos Pantelis (Associated with) 2.Ian Everall (Associated with) 3.Chad Bousman (Associated with)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.4225/49/5a7936cc46b12&rft.title=Treatment-Resistant Schizophrenia Biobank&rft.identifier=https://doi.org/10.4225/49/5a7936cc46b12&rft.publisher=The University of Melbourne&rft.description=Around a third of people who are diagnosed with schizophrenia do not respond to the first-line medication treatment options currently available. The TRS Biobank, set up by the CRC for Mental Health, consists of three distinct groups of participants: volunteers with a diagnosis of schizophrenia, the majority of whom were currently treated with clozapine at the time of assessment (N=114+); first degree relatives of the volunteers with a diagnosis of schizophrenia (N=33+); and unrelated individuals with no issues with mental health (N=67+). Blood, neuroimaging data and other clinical assessment information were collected and maintained by the CRC for Mental Health for use in the identification of biomarkers to assist in developing targeted treatments. The biobank includes: Blood (N=190+): aliquots of serum, plasma, platelets, and red blood cells. Neuroimaging (N=135+): including structural, diffusion-tensor, and resting state imaging collected on a 3T MRI scanner. Neuropsychology (N=200+): including handedness, neurological evaluation, pre-morbid and current IQ, set-shifting, working memory, and spatial span. Clinical (N=200+): including demographics, diagnosis, medication, admissions, positive psychotic symptoms, negative psychotic symptoms, depression, substance use, childhood trauma, and nutrition. The Treatment-Resistant Schizophrenia (TRS) Biobank includes cross-sectional data from more than 200 participants aged over 18, who contributed blood, neuroimaging, neuropsychological, and clinical information between 2012 and 2018. The Cooperative Research Centre (CRC) for Mental Health, working with the Melbourne Neuropsychiatry Centre (Department of Psychiatry, University of Melbourne), have collected data, biological samples and scanned brain images of participants with a diagnosis of schizophrenia, their family members, and healthy control participants to aid in the discovery of biomarkers in the future. The original protocol indicated data within the TRS Biobank could be used for future investigations in the following areas: to discover and validate biomarkers that may be useful for the diagnosis of schizophrenia; to investigate the distinction between sub-types of schizophrenia that may differ in etiology or outcome; to determine which antipsychotic drugs a particular individual diagnosed with schizophrenia may best respond to; and to enhance the monitoring of individual patient response to particular antipsychotics. The TRS Biobank will not be openly accessible; however researchers are able to apply for access to de-identified data for access to de-identified data for individual projects providing independent Human Research Ethics Committee approval and after application review by the CRC. Applications (see application form via the DOI link) can be made to the CRC for Mental Health at: enquiries@mentalhealthcrc.com.&rft.creator=Anonymous&rft.date=2018&rft.relation=http://www.mentalhealthcrc.com/arcitecta-and-the-crc-for-mental-health-to-improve-the-capture-and-management-of-data-from-clinical-research&rft.relation=http://www.sciencedirect.com/science/article/pii/S0920996416301864&rft.relation=http%3A%2F%2Fwww.arcitecta.com%2FFile%3Fi%3D627379%26f%3Dcrc-infographic-a4.pdf%0A&rft_rights=Copyright CRC Mental Health.&rft_subject=Schizophrenia &rft_subject=Biobank&rft_subject=Dna&rft_subject=Rna&rft_subject=Blood&rft_subject=Scanned Images&rft_subject=Psychiatry (Incl. Psychotherapy)&rft_subject=Medical and Health Sciences&rft_subject=Clinical Sciences&rft_subject=Neurosciences Not Elsewhere Classified&rft_subject=Neurosciences&rft_subject=Biomarkers&rft_subject=Psychosis&rft_subject=Mri&rft_subject=Cognition&rft_subject=Melbourne Neuropsychiatry Centre&rft_subject=Mental Health&rft.type=dataset&rft.language=English Access the data

Licence & Rights:

Other view details
Unknown/other

Copyright CRC Mental Health.

Access:

Restrictions apply view details

Collection can be made available to selected users. Follow DOI for access process.

Contact Information

Street Address:
c/-Melbourne Neuropsychiatry Centre
Department of Psychiatry
University of Melbourne



Brief description

The Treatment-Resistant Schizophrenia (TRS) Biobank includes cross-sectional data from more than 200 participants aged over 18, who contributed blood, neuroimaging, neuropsychological, and clinical information between 2012 and 2018. The Cooperative Research Centre (CRC) for Mental Health, working with the Melbourne Neuropsychiatry Centre (Department of Psychiatry, University of Melbourne), have collected data, biological samples and scanned brain images of participants with a diagnosis of schizophrenia, their family members, and healthy control participants to aid in the discovery of biomarkers in the future.

Full description

Around a third of people who are diagnosed with schizophrenia do not respond to the first-line medication treatment options currently available. The TRS Biobank, set up by the CRC for Mental Health, consists of three distinct groups of participants:

  • volunteers with a diagnosis of schizophrenia, the majority of whom were currently treated with clozapine at the time of assessment (N=114+);
  • first degree relatives of the volunteers with a diagnosis of schizophrenia (N=33+); and
  • unrelated individuals with no issues with mental health (N=67+).

Blood, neuroimaging data and other clinical assessment information were collected and maintained by the CRC for Mental Health for use in the identification of biomarkers to assist in developing targeted treatments.

The biobank includes:

  • Blood (N=190+): aliquots of serum, plasma, platelets, and red blood cells.
  • Neuroimaging (N=135+): including structural, diffusion-tensor, and resting state imaging collected on a 3T MRI scanner.
  • Neuropsychology (N=200+): including handedness, neurological evaluation, pre-morbid and current IQ, set-shifting, working memory, and spatial span.
  • Clinical (N=200+): including demographics, diagnosis, medication, admissions, positive psychotic symptoms, negative psychotic symptoms, depression, substance use, childhood trauma, and nutrition.

Notes

The CRC for Mental Health has established large cohorts and uses advanced technological capabilities such as genomics, proteomics, lipidomics and metalomics to identify biomarkers for research into Alzheimer’s disease, Parkinson’s disease, schizophrenia and mood disorders. These biobanks provide an important resource to discover biomarkers in real populations, and ensure our research discoveries are integrated into medical and health care practice.

The CRC for Mental Health is in the process of developing an integrated clinical data management system through collaborations with the data management company Arcitecta, and the support of Research Platform Services, University of Melbourne. This system will allow efficient management and analysis of the Biobank, in addition to the ability to securely share the CRC’s biobank data. The infographic below provides an overview of how the system will function to benefit CRC research. More information on the CRC’s collaboration with Arcitecta can be found online.

Arcitecta Case p1Arcitecta Case p2

The Department of Psychiatry, University of Melbourne has agreed to become the custodian for the Treatment-Resistant Schizophrenia Biobank after 30 June 2018 when the CRC's term expires.

Funding

The Biobank was funded by the Cooperative Research Centre (CRC) for Mental Health. The CRC programme supports industry-led collaborations between industry, researchers and the community.

Significance statement

The original protocol indicated data within the TRS Biobank could be used for future investigations in the following areas:

  • to discover and validate biomarkers that may be useful for the diagnosis of schizophrenia;
  • to investigate the distinction between sub-types of schizophrenia that may differ in etiology or outcome;
  • to determine which antipsychotic drugs a particular individual diagnosed with schizophrenia may best respond to; and
  • to enhance the monitoring of individual patient response to particular antipsychotics.

The TRS Biobank will not be openly accessible; however researchers are able to apply for access to de-identified data for access to de-identified data for individual projects providing independent Human Research Ethics Committee approval and after application review by the CRC. Applications (see application form via the DOI link) can be made to the CRC for Mental Health at: enquiries@mentalhealthcrc.com.

Data time period: 2011-07-01 to 2018-06-30

Click to explore relationships graph